We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+12.84%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.59B
AUM Growth
-$301M
(-6.2%)
Cap. Flow
-$430M
Cap. Flow
% of AUM
-9.37%
Top 10 Holdings %
Top 10 Hldgs %
42.8%
Holding
130
New
21
Increased
24
Reduced
35
Closed
20
Top Buys
| 1 |
AstraZeneca
AZN
|
+$129M |
| 2 |
Merck
MRK
|
+$76.6M |
| 3 |
Guardant Health
GH
|
+$43.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$31.5M |
| 5 |
uniQure
QURE
|
+$28.3M |
Top Sells
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$87M |
| 2 |
Eli Lilly
LLY
|
+$65.3M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$61M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$57.8M |
| 5 |
Cigna
CI
|
+$56.4M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Biogen
BIIB
$28.6B
| $11.3M | 0.25% |
+61,600
| New | +$11.4M |
|
77
Kiniksa Pharmaceuticals
KNSA
$4.7B
| $8.7M | 0.19% |
180,599
-6,600
| -4% | -$292K |
|
78
Keros Therapeutics
KROS
$209M
| $8.38M | 0.18% |
759,155
-45,057
| -6% | -$696K |
|
79
Gilead Sciences
GILD
$163B
| $8.31M | 0.18% |
+59,600
| New | +$8.35M |
|
80
Heron Therapeutics
HRTX
$79.1M
| $7.85M | 0.17% |
+9,816,940
| New | +$11.4M |
|
81
Avalo Therapeutics
AVTX
$976M
| $7.09M | 0.15% |
475,165
-712,135
| -60% | -$11.1M |
|
|
TECX
82
Tectonic Therapeutic
TECX
$624M
| $7M | 0.15% |
226,600
-348,000
| -61% | -$8.56M |
|
83
Adicet Bio
ACET
$80.7M
| $7M | 0.15% |
1,027,944
| – | – |
|
|
CMPS
84
Compass Pathways
CMPS
$1.75B
| $6.36M | 0.14% |
+1,150,646
| New | +$7.74M |
|
85
Pharvaris
PHVS
$2.44B
| $5.8M | 0.13% |
205,400
| – | – |
|
86
ALX Oncology
ALXO
$262M
| $5.75M | 0.13% |
+2,866,256
| New | +$5.46M |
|
87
Artivion
AORT
$1.16B
| $5.53M | 0.12% |
+151,000
| New | +$5.96M |
|
88
InspireMD
NSPR
$33.5M
| $5.11M | 0.11% |
3,133,405
| – | – |
|
89
Revolution Medicines
RVMD
$39.2B
| $5.06M | 0.11% |
52,000
+26,100
| +101% | +$2.64M |
|
90
ADC Therapeutics
ADCT
$158M
| $4.94M | 0.11% |
1,318,026
-4,504,828
| -77% | -$17.8M |
|
91
Protagonist Therapeutics
PTGX
$8.58B
| $4.44M | 0.1% |
42,100
+20,400
| +94% | +$1.81M |
|
92
Palisade Bio
PALI
$330M
| $4.08M | 0.09% |
2,333,000
+461,580
| +25% | +$839K |
|
93
Alto Neuroscience
ANRO
$962M
| $3.77M | 0.08% |
167,500
+42,500
| +34% | +$788K |
|
94
Savara
SVRA
$1.18B
| $3.47M | 0.08% |
+635,000
| New | +$3.53M |
|
95
Cullinan Oncology
CGEM
$1.11B
| $3.45M | 0.08% |
243,006
-27,000
| -10% | -$347K |
|
96
PTC Therapeutics
PTCT
$6.48B
| $3.35M | 0.07% |
49,100
+25,900
| +112% | +$1.83M |
|
97
Lifestance Health
LFST
$4.16B
| $3.19M | 0.07% |
+500,000
| New | +$3.48M |
|
|
DRUG
98
Bright Minds Biosciences
DRUG
$731M
| $2.92M | 0.06% |
+40,000
| New | +$3.22M |
|
|
JBIO
99
Jade Biosciences
JBIO
$1.3B
| $2.6M | 0.06% |
185,011
-346,152
| -65% | -$5.01M |
|
100
C4 Therapeutics
CCCC
$415M
| $2.25M | 0.05% |
856,353
-548,549
| -39% | -$1.29M |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM